2,085 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Park Avenue Securities LLC

Park Avenue Securities LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,085 shares of the biopharmaceutical company’s stock, valued at approximately $680,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ALNY. SVB Wealth LLC acquired a new stake in Alnylam Pharmaceuticals during the 1st quarter worth approximately $27,000. Whipplewood Advisors LLC increased its position in Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 71 shares in the last quarter. Bessemer Group Inc. increased its position in Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 69 shares in the last quarter. Washington Trust Advisors Inc. increased its position in Alnylam Pharmaceuticals by 53.5% during the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 61 shares in the last quarter. Finally, Larson Financial Group LLC increased its position in Alnylam Pharmaceuticals by 77.7% during the 1st quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 87 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 6,979 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $3,163,371.33. Following the transaction, the chief executive officer directly owned 56,221 shares in the company, valued at $25,483,292.67. This trade represents a 11.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Jeffrey V. Poulton sold 2,274 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $1,030,735.98. Following the transaction, the executive vice president owned 50,121 shares in the company, valued at $22,718,345.67. This trade represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 75,594 shares of company stock worth $33,968,256. 1.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on ALNY. Jefferies Financial Group increased their target price on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a “buy” rating in a research report on Monday, July 7th. UBS Group upped their price target on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Bank of America upped their price target on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th. Raymond James Financial began coverage on Alnylam Pharmaceuticals in a report on Wednesday, July 30th. They issued an “outperform” rating and a $370.00 price target for the company. Finally, Chardan Capital upped their price target on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Twenty-four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $439.58.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $446.40 on Monday. The stock has a market cap of $58.51 billion, a P/E ratio of -180.73 and a beta of 0.32. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The stock has a 50 day moving average of $428.51 and a 200-day moving average of $332.71. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. The company had revenue of $773.69 million during the quarter, compared to analysts’ expectations of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business’s revenue was up 17.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.